Achyut Healthcare Limited is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 4 | 3 | 6 | 3 | 12 |
| EBITDA (ex other income) | — | — | — | — | 0 |
| margin % | — | — | — | — | 1.5 |
| Owners' profit | — | — | — | — | 0 |
| EPS, as reported (₹) | 0.15 | 0.03 | 0.34 | 0.02 | 0.01 |
| ROE % · ROCE % | — · 1.1 | — · 2.1 | — · 2.4 | — · 2.2 | 0.9 · 1.1 |
| Debt / equity (x) | — | — | — | — | 0.00 |
| Cash from operations | (7) | 0 | 0 | (4) | 1 |
| Capex | — | — | — | (11) | (8) |
| ₹ crore | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 5 | 2 | 1 | 6 | 2 | 4 | 3 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | — | — | — | — | — | 0 | 0 | 0 |
| EPS (₹) | 0.19 | 0.21 | 0.21 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 5 Sept 2026 · Achyut Healthcare files 31st Annual Report for FY25-26, AGM on 29 September | compliance | minimal | — | — |
| 5 Sept 2026 · Achyut Healthcare submits 31st Annual Report; AGM on 29 Sept 2026 | compliance | medium | — | — |
| 5 Sept 2026 · Achyut Healthcare 31st AGM cut-off date set for 22 Sep 2026 | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Achyut Healthcare re-appoints MD and two Independent Directors for 5 years | management changes | high | — | — |
| 5 Sept 2026 · Board approves AGM notice and re-appoints MD and two Independent Directors | board shareholder meetings | low | — | — |
| 5 Sept 2026 · 31st AGM notice on Sep 29, 2026 with director re-appointments | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Board okays AGM on Sep 29, re-appoints MD and 2 directors for 5 years | board shareholder meetings | medium | — | — |
| 14 Aug 2026 · Achyut Healthcare submits Q1 FY26 results newspaper cuttings to BSE | compliance | minimal | — | — |
| 13 Aug 2026 · No deviation in use of public issue funds for Q1 FY27 | compliance | minimal | — | — |
| 13 Aug 2026 · Achyut Healthcare Q1 FY27 unaudited results approved by board | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| CIPLA LTD |
| 1,10,352 |
| 32.7 |
| 3.20 |
| 16.9 |
| 11.2 |
| 14.7 |
| 8.0 |
| 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 231.3 | 28.9 | 166 of 169 | 2% |
| P/B | 4.8 | 3.3 | 112 of 163 | 32% |
| ROCE | 1.0 | 10.8 | 148 of 183 | 19% |
| ROE | 0.9 | 10.4 | 143 of 171 | 17% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 7.5 | 17.5 | 132 of 165 | 20% |
| Revenue growth | 239.6 | 16.3 | 4 of 161 | 98% |
| Market cap | 168 | 839 | 122 of 182 | 33% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
